{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:46Z","timestamp":1788454846267,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","award":["2020ZSQN53"],"award-info":[{"award-number":["2020ZSQN53"]}],"id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["shslczdzk06504"],"award-info":[{"award-number":["shslczdzk06504"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejphar.2025.177777","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T19:00:06Z","timestamp":1748458806000},"page":"177777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Toward precision dosing of linezolid in critical ill patients: efficiency and risk of thrombocytopenia analysis by population PKPD modeling and simulations"],"prefix":"10.1016","volume":"1002","author":[{"given":"Yan","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Rong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Zhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177777_bib1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0091270009337947","article-title":"Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients","volume":"49","author":"Abe","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177777_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01174-20","article-title":"Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis","volume":"64","author":"Alghamdi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib3","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40262-020-00964-1","article-title":"Supra-therapeutic linezolid trough concentrations in elderly patients: a call for action?","volume":"60","author":"Cattaneo","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2025.177777_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2025.177777_bib6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2025.177777_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.medmal.2013.09.011","article-title":"The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia","volume":"43","author":"Chavanet","year":"2013","journal-title":"Med. Maladies Infect."},{"key":"10.1016\/j.ejphar.2025.177777_bib8","first-page":"383","article-title":"Determination of linezolid in human plasma by LC-MS\/MS","volume":"26","author":"Chen","year":"2021","journal-title":"Chin J Clin Pharma"},{"key":"10.1016\/j.ejphar.2025.177777_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40262-020-00937-4","article-title":"Can population pharmacokinetics of antibiotics be extrapolated? Implications of external evaluations","volume":"60","author":"Cheng","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2025.177777_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00451-18","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers","volume":"62","author":"Cho","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jval.2015.04.007","article-title":"Linezolid versus Vancomycin in the empiric treatment of nosocomial pneumonia: a cost-utility analysis incorporating results from the ZEPHyR trial","volume":"18","author":"Collins","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.ejphar.2025.177777_bib12","first-page":"7","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"4","author":"Dryden","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-020-03080-y","article-title":"Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model","volume":"77","author":"Gu","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177777_bib14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11096-021-01342-y","article-title":"Risk factors for linezolid-induced thrombocytopenia in adult inpatients","volume":"44","author":"Han","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.ejphar.2025.177777_bib15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177777_bib16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.177777_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/asheducation-2016.1.251","article-title":"Platelets in liver and renal disease","author":"Lambert","year":"2016","journal-title":"Hematology Am. Soc. Hematol Educ. Program"},{"key":"10.1016\/j.ejphar.2025.177777_bib18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2025.177777_bib19","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41401-022-00892-9","article-title":"Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.177777_bib20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/FTD.0000000000000665","article-title":"Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity","volume":"41","author":"Luque","year":"2019","journal-title":"Ther. Drug Monit."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2025.177777_bib21","first-page":"i17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2025.177777_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.47.2.548-553.2003","article-title":"Population pharmacokinetics of linezolid in patients treated in a compassionate-use program","volume":"47","author":"Meagher","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020253","article-title":"Population pharmacokinetic model of linezolid and probability of target attainment in patients with COVID-19-Associated acute respiratory distress syndrome on veno-venous extracorporeal membrane Oxygenation-A step toward correct dosing","volume":"16","author":"Milakovic","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.177777_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40262-016-0463-7","article-title":"Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients","volume":"56","author":"Minichmayr","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2025.177777_bib26","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib27","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib28","unstructured":"Perl-speaks-NONMEM. https:\/\/uupharmacometrics.github.io\/PsN\/index.html (accessed 9 April 2025)."},{"key":"10.1016\/j.ejphar.2025.177777_bib29","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1111\/bcp.15368","article-title":"Parametric population pharmacokinetics of linezolid: a systematic review","volume":"88","author":"Qin","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177777_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2025.177777_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/phar.2719","article-title":"Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients","volume":"42","author":"Sakurai","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2025.177777_bib32","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/138920011796504527","article-title":"Age-related changes in pharmacokinetics","volume":"12","author":"Shi","year":"2011","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.ejphar.2025.177777_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131932","article-title":"Predictors of clinical success in the treatment of patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP)","volume":"10","author":"Shorr","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177777_bib35","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2025.177777_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010054","article-title":"Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation","volume":"12","author":"Soraluce","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2025.177777_bib37","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1128\/AAC.00356-16","article-title":"Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients","volume":"60","author":"Taubert","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2025.177777_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00228-017-2303-6","article-title":"Is it time to revise linezolid dose in elderly patients?","volume":"73","author":"Tinelli","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177777_bib39","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177777_bib40","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2147\/DDDT.S303497","article-title":"Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, Open-Label, observational Study","volume":"15","author":"Wang","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2025.177777_bib41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2017.06.023","article-title":"Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study","volume":"50","author":"Wicha","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2025.177777_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106572","article-title":"Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients","volume":"59","author":"Wicha","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2025.177777_bib43","article-title":"Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500531X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500531X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:21:24Z","timestamp":1778876484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992500531X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"alternative-id":["S001429992500531X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177777","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward precision dosing of linezolid in critical ill patients: efficiency and risk of thrombocytopenia analysis by population PKPD modeling and simulations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177777"}}